Aberrant methylation of tumour-related genes in thymic epithelial tumours

Lung Cancer

Volumn 64, Issue 2, 2009, Pages 155-159

  Hirose, Yukiko ^a   Kondo, Kazuya ^a   Takizawa, Hiromitsu ^a   Nagao, Taeko ^a   Nakagawa, Yasushi ^a   Fujino, Haruhiko ^a   Toba, Hiroaki ^a   Kenzaki, Koichiro ^a   Sakiyama, Shoji ^a   Tangoku, Akira ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cancer related genes; DNA methylation; O6 methylguanine DNA methyltransferase; Thymic carcinoma; Thymoma

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; MEMBRANE PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN HPP1; PROTEIN P16; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; THYMOMA; THYMUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARCINOMA; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENES, P16; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; THYMOMA; THYMUS NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 63049111822     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.07.015     Document Type: Article

References (36)

1. Rosai J., and Levine G.D. Tumor of the thymus. Atlas of tumor pathology, 2nd series fascicle 13 (1976), Armed Forces Institute of Pathology, Washington, DC
2. Shimosato Y., and Mukai K. Tumors of the mediastinum. Atlas of tumor pathology, 3rd series fascicle 21 (1997), Armed Forces Institute of Pathology, Washington, DC
3. Shimosato Y. Controversies surrounding the subclassification of thymoma. Cancer 74 (1994) 542-544
4. Rosai J. Histological typing of tumours of the thymus. WHO International histological classification of tumours. 2nd ed. (1999), Springer-Verlag, New York pp. 5-15
5. Travis W.D., Brambilla E., Muller-Hermelink H.K., and Harris C.C. Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO classification of tumours. 2nd ed. (2004), IARC Press, Lyon pp. 145-97
6. Nomori H., Horinouchi H., Kaseda S., Ishihara T., and Torikata C. Evaluation of malignant grade of thymoma by morphometric analysis. Cancer 61 (1998) 982-988
7. Asamura H., Nakajima T., Mukai K., Noguchi M., and Shimosato Y. Degree of malignancy of thymic epithelial tumors in terms of nuclear DNA content and nuclear area. An analysis of 39 cases. Am J Pathol 133 (1988) 615-622
8. Yang W.I., Efird J.T., Quintanilla-Martinez L., Choi N., and Harris N.L. Cell kinetic study of thymic epithelial tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies. Hum Pathol 27 (1996) 70-76
9. Pich A., Chiarle R., Chiusa L., and Palestro G. Argyrophilic nucleolar organizer region counts predict survival in thymoma. Cancer 74 (1994) 1568-1574
10. Hino N., Kondo K., Miyoshi T., Uyama T., and Monden Y. High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer 76 (1997) 1361-1366
11. Sogawa K., Kondo K., Fujino H., Takahashi Y., Miyoshi T., Sakiyama S., et al. Increased expression of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 correlate with poor prognostic variables in thymic epithelial tumors. Cancer 98 (2003) 1822-1829
12. Suzuki M., Chen H., Shigematu H., Ando S., Iida T., Nakajima T., et al. Aberrant methylation in thymic carcinomas, rare in thymomas. Oncol. Rep. 14 (2005) 1621-1624
13. Hirabayashi H., Fujii Y., Sakaguchi M., Tanaka H., Yoon H., Komoto Y., et al. p16 INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 73 (1997) 639-644
14. Zettl A., Ströbel P., Wagner K., Katzenberger T., Ott G., Rosenwald A., et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 157 (2000) 257-266
15. Zhou R., Zettl A., Ströbel P., Wagner K., Müller-Hermelink H.K., Zhang S.J., et al. Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol 159 (2001) 1853-1860
16. Inoue M., Starostik P., Zettl A., Ströbel P., Schwarz S., Scaravilli F., et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 63 (2003) 3708-3715
17. Jass J.R. Colorectal cancer: a multipathway disease. Crit Rev Oncog 12 (2006) 273-287
18. Oyama T., Osaki T., Mitsudomi T., Ogawa R., Nakanishi R., Sugio K., et al. p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med 1 (1998) 823-826
19. Weirich G., Schneider P., Fellbaum C., Brauch H., Narthrath W., Scholz M., et al. p53 alterations in thymic epithelial tumours. Virchows Arch 431 (1997) 17-23
20. Masaoka A., Monden Y., Nakahara K., and Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 (1981) 2485-2492
21. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
22. Zöchbauer-Müller S., FongKM, Virmani A.K., Geradts J., Gazdar A.F., and Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61 (2001) 249-255
23. Tsou J., Hagen J., Carpenter C., and Laird-Offringa I. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21 (2002) 5450-5461
24. Belinsky S., Palmisano W., Gilliland F., Crooks L., Divine K., Winters S., et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62 (2002) 2370-2377
25. Kondo K., Yoshizawa K., Tsuyuguchi M., Kimura S., Sumitomo M., Morita J., et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg 77 (2004) 1183-1188
26. Detterbeck F. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg 81 (2006) 2328-2334
27. Pegg A.E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50 (1990) 6119-6129
28. Jacinto F., and Esteller M. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair 6 (2007) 1155-1160
29. Brabender J., Usadel H., Metzger R., Schneider P., Park J., Salonga D., et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res 9 (2003) 223-227
30. Komine C., Watanabe T., Katayama Y., Yoshino A., Yokoyama T., and Fukushima T. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13 (2003) 176-184
31. Koga Y., Kitajima Y., Miyoshi A., Sato K., Kitahara K., Soejimaand H., et al. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers. Ann Surg Oncol 12 (2005) 354-363
32. Esteller M., Garcia-Foncillas J., Andion E., Goodman S., Hidalgo O., Vanaclocha V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000) 1350-1354
33. Esteller M., Gaidano G., Goodman S., Zagonel V., Capello D., Botto B., et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94 (2002) 26-32
34. Loehrer P.J., Kim K.M., Aisner S.C., Livingston R., Einhorn L.H., Johnson D., et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. J Clin Oncol 12 (1994) 1164-1168
35. Loehrer P.J., Jiroutek M., Aisner S., Aisner j, Green M., Thomas Jr. L.R., et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial. Cancer 91 (2001) 2010-2015
36. Belinsky S.A., Klinge D.M., Dekker J.D., Smith M.W., Bocklage T.J., Gilliland F.D., et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11 (2005) 6505-6518